| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_067a3c5fff599aa564fefd4d03be8fde
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4c09430bd69604ea661ae93f4525cd0c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70557
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-43527
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2848
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-6462
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-21073 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-49
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 |
| filingDate |
2020-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9c13eb504ddb5f22448bf2169880b7f9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9478c0952a8a522eea5d35b4574f0a48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2022c37751efec946717388583092990
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df50cb384724c86c305aed40f404b077
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_87edf8861af01b67f08d689a5870c21f |
| publicationDate |
2020-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2020237307-A1 |
| titleOfInvention |
Chimeric molecules comprising an anti-coagulant agent and an anti-gpiib/iiia antigen binding molecule and uses thereof |
| abstract |
Disclosed are anti-thrombotic agents. More particularly, chimeric molecules are disclosed, which target multiple pathways in the coagulation cascade and which comprise an anti-coagulant agent and an anti-platelet antigen-binding molecule that binds to the active conformation of platelet integrin receptor GPIIb/IIIa with greater affinity than to its inactive conformation. In specific embodiments of the present disclosure, the chimeric molecules are used alone or in combination with other agents in compositions and methods for inhibiting thrombus and/or embolus formation and for treating or inhibiting the development of conditions associated with the presence of activated platelets. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114032280-A |
| priorityDate |
2019-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |